<DOC>
	<DOCNO>NCT00073450</DOCNO>
	<brief_summary>The purpose study determine safety efficacy oral Farnesyl Protein Transferase Inhibitor ( Lonafarnib/SCH 6636 ) single agent Adult Patients With Squamous Cell Carcinoma Head &amp; Neck help determine development justified .</brief_summary>
	<brief_title>Study Lonafarnib Patients With Recurrent Squamous Cell Carcinoma Head Neck ( Study P02530 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Histologically cytologically proven squamous cell carcinoma head &amp; neck . Age great equal 18 . ECOG performance status 0 1 Measurable malignant disease . Patients fail least one platinumcontaining regimen receive three prior regimen curative treatment option . Patients must least 2 wks post surgery radiation therapy Patients must least 4 week post chemotherapy Meets protocol requirement specify laboratory value . Written inform consent cooperation patient . Appropriate use effective contraception childbearing potential . No investigational drug type within 30 day prior administration . Prior exposure farnesyl transferase inhibitor Medical condition would interfere take oral medication . Patients significant QTc prolongation baseline ( &gt; 500 msec . ) Pregnant nursing woman Known HIV positivity AIDSrelated illness . Concomitant chemotherapy , hormonal therapy , radiotherapy immunotherapy Patients sign involvement dura , meninges , brain . Patients squamous cell carcinoma nasopharynx Patients currently cancer treat last 5 year malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Squamous Cell Carcinoma Head &amp; Neck</keyword>
</DOC>